SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Condition:   Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions:   Drug: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors:   RTOG Foundation, Inc.;   Merck Sharp & Dohme Corp.
Not yet recruiting

https://ift.tt/2M19Wqa